15,800 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Acquired by Natixis

Natixis purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,800 shares of the biopharmaceutical company's stock, valued at approximately $399,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its position in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics during the 4th quarter worth about $81,000. KBC Group NV lifted its holdings in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC boosted its position in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after buying an additional 2,705 shares in the last quarter. Finally, Aristides Capital LLC bought a new stake in Celldex Therapeutics during the fourth quarter worth about $202,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CLDX shares. The Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research note on Monday. They issued a "buy" rating and a $64.00 price objective on the stock. UBS Group initiated coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price for the company. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock traded down $0.10 during trading on Wednesday, hitting $20.83. 684,578 shares of the company were exchanged, compared to its average volume of 884,828. The firm has a market capitalization of $1.38 billion, a P/E ratio of -8.11 and a beta of 1.59. The firm's fifty day moving average price is $19.11 and its 200 day moving average price is $23.34. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.